전립선암 호르몬 요법 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2024-2032년)

Growth Factors of prostate cancer hormone therapy Market

The global prostate cancer hormone therapy market is witnessing robust growth as prostate cancer prevalence continues to rise and treatment innovations advance rapidly. According to the latest industry estimates, the market was valued at USD 16.07 billion in 2024, is expected to reach USD 20.44 billion in 2025, and is projected to surge to USD 79.93 billion by 2032, demonstrating the strong demand for hormone-based treatment options across global healthcare systems. In 2024, North America dominated the market with a 51.71% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and high awareness of early cancer diagnosis.

Hormone therapy remains a cornerstone of prostate cancer management. Also known as Androgen Deprivation Therapy (ADT), this treatment reduces hormone levels that fuel tumor growth and is widely used in metastatic and advanced-stage cancers. With global cancer burden intensifying-GLOBOCAN 2022 recorded 1.47 million prostate cancer cases, making it the 4th most common cancer-there is rising dependence on hormone therapy as a core treatment approach.

Market Drivers

The development of advanced hormonal therapies is a major market driver. Leading pharmaceutical companies are introducing new androgen receptor inhibitors and next-generation GnRH-based therapies to overcome resistance and improve patient outcomes. In November 2023, Astellas Pharma and Pfizer received FDA approval for XTANDI for non-metastatic Castration-Sensitive Prostate Cancer, enabling broader treatment use.

Strong R&D pipelines and increasing clinical trials continue to accelerate therapeutic innovation. The rising global incidence of prostate cancer, coupled with expanding access to advanced therapies in developed nations, also supports continuous market growth.

Market Restraints

A significant restraint is the growing resistance to conventional ADT. Over time, prostate cancer cells may mutate and continue producing androgens, diminishing therapeutic effectiveness. For instance, research in January 2024 by Sylvester Comprehensive Cancer Center revealed that the enzyme 3BHSD1 enables tumors to regenerate androgens even during hormone suppression therapy, accelerating disease progression. This resistance challenges treatment efficacy and limits long-term therapy adoption.

Market Challenges

Patients undergoing hormonal therapy often experience substantial side effects, making treatment adherence challenging. Erectile dysfunction and libido loss are common complications. A study published by Elsevier in 2020 reported that 82% of ADT patients experienced erectile problems, while 64% reported loss of sexual desire, negatively affecting quality of life. Such adverse effects remain a major barrier to therapy continuation.

Market Opportunities

Combination therapies offer significant future opportunities. Pharmaceutical companies are increasingly exploring combinations of PARP inhibitors with ADT to address resistance and extend survival. In February 2025, the TALAPRO-2 trial demonstrated that combining talazoparib (Talzenna) with enzalutamide (Xtandi) provided a 14-month improvement in overall survival for HRR-deficient metastatic prostate cancer patients, with a 38% reduction in mortality risk. These outcomes highlight the strong potential of combination therapy in shaping the future treatment landscape.

Segmentation Overview

By Drug Class

In 2024, GnRH agonists held the leading share due to high effectiveness in testosterone suppression. Regulatory approvals for products like CAMCEVI continue strengthening this segment. GnRH receptor antagonists and androgen receptor inhibitors are expected to grow substantially due to multiple new approvals and expanded clinical indications.

By Disease State

The metastatic castration-resistant prostate cancer (mCRPC) segment dominated in 2024, driven by rising incidence and increased approvals of targeted therapies. The non-metastatic CRPC segment is set for strong growth as companies broaden their indications.

By Route of Administration

The oral segment held the largest share due to ease of administration and growing generic launches, such as Amneal's FDA-approved generic Abiraterone Acetate. The parenteral segment continues to expand with new injectable formulations under trial.

By Distribution Channel

Hospital pharmacies lead due to specialized cancer treatment centers and physician-supervised therapy administration. Retail and online pharmacies are growing steadily due to improved drug accessibility.

Regional Outlook

North America

The market reached USD 8.31 billion in 2024, driven by high prostate cancer incidence and advanced therapeutic adoption. Strong R&D presence and FDA approvals contribute to regional dominance.

Europe

Europe holds the second-largest share, supported by healthcare authority endorsements. In 2024, NICE recommended ORGOVYX as a cost-effective treatment option.

Asia Pacific

Expected to be the fastest-growing region due to rising aging populations and increasing therapy approvals. In July 2024, China's NMPA approved XTANDI for metastatic disease.

Latin America & Middle East/Africa

Moderate growth is expected, driven by rising collaborations and gradual improvements in prostate cancer treatment access.

Conclusion

The global prostate cancer hormone therapy market is on a strong growth trajectory, rising from USD 16.07 billion in 2024 to USD 20.44 billion in 2025, and projected to reach USD 79.93 billion by 2032. With expanding treatment innovations, increasing approvals, and strong R&D momentum, hormone therapy remains central to the future of prostate cancer care.

Segmentation By Drug Class

• Androgen Receptor Inhibitors
• Gonadotropin Releasing Hormone (GnRH) Agonist
• Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
• Others

By Route of Administration

• Oral
• Parenteral

By Disease State

• Metastatic Castration-Resistant Prostate Cancer
• Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region

• North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, by Key Players
• 4.3. Overview of Alternative Therapies
• 4.4. Key Start-ups in the Market
• 4.5. New Product Launches, by Key Players
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Androgen Receptor Inhibitors
  • 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
• 5.3. Market Analysis, Insights and Forecast - By Disease State
  • 5.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Drug Stores & Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Androgen Receptor Inhibitors
  • 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
• 6.3. Market Analysis, Insights and Forecast - By Disease State
  • 6.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Drug Stores & Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Androgen Receptor Inhibitors
  • 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
• 7.3. Market Analysis, Insights and Forecast - By Disease State
  • 7.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Drug Stores & Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Androgen Receptor Inhibitors
  • 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
• 8.3. Market Analysis, Insights and Forecast - By Disease State
  • 8.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Drug Stores & Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Androgen Receptor Inhibitors
  • 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
• 9.3. Market Analysis, Insights and Forecast - By Disease State
  • 9.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Drug Stores & Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Androgen Receptor Inhibitors
  • 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
  • 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
• 10.3. Market Analysis, Insights and Forecast - By Disease State
  • 10.3.1. Metastatic Castration-Resistant Prostate Cancer
  • 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Drug Stores & Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. Astellas Pharma Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Pfizer Inc.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Johnson & Johnson Services, Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Ferring Pharmaceuticals Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. AbbVie Inc.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. AstraZeneca
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Accord BioPharma, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Bayer AG
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)